Health · Ai
Glycyx
Glycyx is a San Francisco biopharmaceutical company developing axelopran, an orally administered peripheral mu-opioid receptor antagonist, to counter opioid-induced immunodeficiency in cancer patients. Roughly 45% of immunotherapy patients take opioids for pain, and studies link that use to sharply worse outcomes on checkpoint inhibitors. Axelopran blocks opioid signaling on immune cells - without touching pain relief - to restore T-cell infiltration into tumors and make 'cold' tumors respond to immunotherapy. The company is Phase 2b-ready with an active IND and has drawn NIH SBIR grant support.